Antibodies that bind Notum Pectinacetylesterase

Inventors: Robert Joseph Brommage, Jr. (The Woodlands, TX); Xiao Feng (The Woodlands, TX); Seokjoo Hong (The Woodlands, TX); Gregory Landes (San Bruno, CA); Jeff Liu (The Woodlands, TX); David George Potter (The Woodlands, TX); David Reed Powell (Houston, TX)

Assignee: Lexicon Pharmaceuticals, Inc.

C07K16/40 A61K39/3955 A61K2039/505 C07K2317/14 C07K2317/24 C07K2317/33 C07K2317/51 C07K2317/515 C07K2317/565 C07K2317/76 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,059,907
App. No.: 16/277,466
Granted: Jul 13, 2021
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.

Claims (45)

1. A method of stimulating endocortical bone formation in a patient in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising a monoclonal antibody that binds to human notum pectinacetylesterase (NOTUM) and neutralizes at least one activity of NOTUM, wherein the antibody binds to a region of NOTUM from amino acids 47 to 177 of SEQ ID NO: 1, and wherein the antibody reduces NOTUM activity in a trisodium 8-octanoyloxypyrene-1,3,6-trisulfonate (OPTS) assay in vitro and reduces NOTUM activity in a Wnt signaling assay in vitro, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein:

a) the heavy chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 17, a CDR2 having the amino acid sequence of SEQ ID NO: 18, and a CDR3 having the amino acid sequence of SEQ ID NO: 19, and the light chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 20, a CDR2 having the amino acid sequence of SEQ ID NO: 21, and a CDR3 having the amino acid sequence of SEQ ID NO: 22;

b) the heavy chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 25, a CDR2 having the amino acid sequence of SEQ ID NO: 26, and a CDR3 having the amino acid sequence of SEQ ID NO: 27, and wherein the light chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 28, a CDR2 having the amino acid sequence of SEQ ID NO: 29, and a CDR3 having the amino acid sequence of SEQ ID NO: 30;

c) the heavy chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 33, a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a CDR3 having the amino acid sequence of SEQ ID NO: 35, and the light chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 36, a CDR2 having the amino acid sequence of SEQ ID NO: 37, and a CDR3 having the amino acid sequence of SEQ ID NO: 38; or

d) the heavy chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 57, a CDR2 having the amino acid sequence of SEQ ID NO: 58, and a CDR3 having the amino acid sequence of SEQ ID NO: 59, and wherein the light chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 60, a CDR2 having the amino acid sequence of SEQ ID NO: 61, and a CDR3 having the amino acid sequence of SEQ ID NO: 62.

2. The method of claim 1 , wherein the antibody increases serum Procollagen I N-terminal Propeptide (PINP) levels in vivo, increases bone mineral density in vivo, increases midshaft femur cortical thickness in vivo, increases midshaft femur bone area in vivo, increases midshaft humerus cortical thickness in vivo, increases endocortical bone formation in vivo, increases the proportion of cortical bone volume in the LV5 vertebral body in vivo, and/or increases the proportion of femoral neck bone volume to femoral neck total volume in vivo.

3. The method of claim 1 , wherein the antibody is selected from a chimeric antibody, a humanized antibody, and a human antibody.

4. The antibody of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 15, 23, 31, 55, 63, 71, 75, and 79.

5. The antibody of claim 1 , wherein the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 16, 24, 32, 56, 65, 73, 77, and 81.

6. The antibody of claim 1 , wherein:

a) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 15 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16;

b) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 73;

c) the heavy chain comprises the amino acid sequence of SEQ ID NO: 72 and the light chain comprises the amino acid sequence of SEQ ID NO: 74;

d) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 23 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 24;

e) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 75 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 77;

f) the heavy chain comprises the amino acid sequence of SEQ ID NO: 76 and the light chain comprises the amino acid sequence of SEQ ID NO: 78;

g) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 32;

h) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 79 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 81;

i) the heavy chain comprises the amino acid sequence of SEQ ID NO: 80 and the light chain comprises the amino acid sequence of SEQ ID NO: 82;

j) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 55 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 56;

k) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65; or

l) the heavy chain comprises the amino acid sequence of SEQ ID NO: 64 and the light chain comprises the amino acid sequence of SEQ ID NO: 66.

7. A method of treating, managing, or preventing a disease or disorder characterized by bone loss in a patient, comprising administering an effective amount of a pharmaceutical composition comprising a monoclonal antibody that binds to human notum pectinacetylesterase (NOTUM) and neutralizes at least one activity of NOTUM, wherein the antibody binds to a region of NOTUM from amino acids 47 to 177 of SEQ ID NO: 1, and wherein the antibody reduces NOTUM activity in a trisodium 8-octanoyloxypyrene-1,3,6-trisulfonate (OPTS) assay in vitro and reduces NOTUM activity in a Wnt signaling assay in vitro, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein:

8. The method of claim 7 , wherein the disease or disorder is osteoporosis.

9. The method of claim 7 , wherein the antibody increases serum Procollagen I N-terminal Propeptide (PINP) levels in vivo, increases bone mineral density in vivo, increases midshaft femur cortical thickness in vivo, increases midshaft femur bone area in vivo, increases midshaft humerus cortical thickness in vivo, increases endocortical bone formation in vivo, increases the proportion of cortical bone volume in the LV5 vertebral body in vivo, and/or increases the proportion of femoral neck bone volume to femoral neck total volume in vivo.

10. The method of claim 7 , wherein the antibody is selected from a chimeric antibody, a humanized antibody, and a human antibody.

11. The antibody of claim 7 , wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 15, 23, 31, 55, 63, 71, 75, and 79.

12. The antibody of claim 7 , wherein the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 16, 24, 32, 56, 65, 73, 77, and 81.

13. The antibody of claim 7 , wherein: